Vimarsana
Biggest News Aggregation in the World

Priority Review Designations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Priority Review Designations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Priority Review Designations Today - Breaking & Trending Today

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting - Vimarsana News

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company…

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ... - Vimarsana News

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ...

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut

Source: menafn.com
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates - Vimarsana News

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress - Vimarsana News

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Vimarsana News

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio Inc. , a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced...